Cargando…

Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?

BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hissink Muller, Petra C. E., Yildiz, Bahar, Allaart, Cornelia F., Brinkman, Danielle M. C., van Rossum, Marion, van Suijlekom-Smit, Lisette W. A., van den Berg, J. Merlijn, ten Cate, Rebecca, de Vries, Martine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302476/
https://www.ncbi.nlm.nih.gov/pubmed/30572875
http://dx.doi.org/10.1186/s12910-018-0336-8
_version_ 1783381988230561792
author Hissink Muller, Petra C. E.
Yildiz, Bahar
Allaart, Cornelia F.
Brinkman, Danielle M. C.
van Rossum, Marion
van Suijlekom-Smit, Lisette W. A.
van den Berg, J. Merlijn
ten Cate, Rebecca
de Vries, Martine C.
author_facet Hissink Muller, Petra C. E.
Yildiz, Bahar
Allaart, Cornelia F.
Brinkman, Danielle M. C.
van Rossum, Marion
van Suijlekom-Smit, Lisette W. A.
van den Berg, J. Merlijn
ten Cate, Rebecca
de Vries, Martine C.
author_sort Hissink Muller, Petra C. E.
collection PubMed
description BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a less favoured treatment-strategy. METHODS: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase 1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were conducted with 23 parents and 7 patients, median 11 months after enrolment. RESULTS: Initially most parents and children were not in equipoise. Parents/patients who refused participation, regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy. They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy, but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the treatment actually received. CONCLUSIONS: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the physicians’ research question is in line with preferences of the patient-group. By exploring so-called ‘informed patient-group’-equipoise, successful recruitment may be enhanced and bias avoided. In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by comparable outcomes in all three arms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12910-018-0336-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6302476
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63024762018-12-31 Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? Hissink Muller, Petra C. E. Yildiz, Bahar Allaart, Cornelia F. Brinkman, Danielle M. C. van Rossum, Marion van Suijlekom-Smit, Lisette W. A. van den Berg, J. Merlijn ten Cate, Rebecca de Vries, Martine C. BMC Med Ethics Research Article BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a less favoured treatment-strategy. METHODS: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase 1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were conducted with 23 parents and 7 patients, median 11 months after enrolment. RESULTS: Initially most parents and children were not in equipoise. Parents/patients who refused participation, regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy. They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy, but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the treatment actually received. CONCLUSIONS: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the physicians’ research question is in line with preferences of the patient-group. By exploring so-called ‘informed patient-group’-equipoise, successful recruitment may be enhanced and bias avoided. In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by comparable outcomes in all three arms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12910-018-0336-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-20 /pmc/articles/PMC6302476/ /pubmed/30572875 http://dx.doi.org/10.1186/s12910-018-0336-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hissink Muller, Petra C. E.
Yildiz, Bahar
Allaart, Cornelia F.
Brinkman, Danielle M. C.
van Rossum, Marion
van Suijlekom-Smit, Lisette W. A.
van den Berg, J. Merlijn
ten Cate, Rebecca
de Vries, Martine C.
Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title_full Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title_fullStr Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title_full_unstemmed Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title_short Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
title_sort participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302476/
https://www.ncbi.nlm.nih.gov/pubmed/30572875
http://dx.doi.org/10.1186/s12910-018-0336-8
work_keys_str_mv AT hissinkmullerpetrace participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT yildizbahar participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT allaartcorneliaf participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT brinkmandaniellemc participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT vanrossummarion participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT vansuijlekomsmitlisettewa participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT vandenbergjmerlijn participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT tencaterebecca participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise
AT devriesmartinec participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise